drugset / Trial / NCT00775814

Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.

NCT00775814

Phase 4 Completed 188 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy of candesartan, once daily (QD), combined with hydrochlorothiazide to lower blood pressure in insulin-resistant, obese patients with hypertension.

Timeline

Start
2006-10
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan Unknown 16 mg Oral
Comparator Hydrochlorothiazide Unknown 12.5 mg Oral